http://www.biofortuna.com Just another WordPress weblog Thu, 02 Sep 2010 11:39:50 +0000 http://backend.userland.com/rss092 en Prior to joining Biofortuna Harry was a Consultant offering business analysis services to the Pharmaceutical and Life Science sectors. Before this he was Director of Operations at London Genetics, a company providing pharmacogenomic research projects to the pharma and biotech industry. At DxS, a personalized medicine company, he was a ... http://www.biofortuna.com/index.php/staff-directors/harry-singh/ Although we have no current vacancies, Biofortuna does plan to expand over the next year in the areas of R&D, Production, Sales, Bioinformatics, Marketing and Product Management; consequently if you are interested in a job with a forward-thinking, exciting employer then we would be pleased to hold your CV and ... http://www.biofortuna.com/index.php/jobs/career-opportunities/ Geoff joins Biofortuna as a part-time Financial Director; Geoff is an experienced finance professional who has worked with various small, medium and large businesses including Altrix, Concateno, Paver Downes, Enterprise Care Group, Gemini Holdings and Novolytics. Email: geoff.orme@biofortuna.com http://www.biofortuna.com/index.php/staff-directors/geoff-orme/ David Whitcombe is an experienced biotech director who brings a wealth of experience in successfully developing quality diagnostics and in growing biotechnology companies. David was previously part of the successful founding team of DXS, a North West UK based Molecular Diagnostics company which sold to Qiagen in 2009 in a ... http://www.biofortuna.com/index.php/staff-directors/dr-david-whitcombe/ UK-based venture and growth capital funds EV and Catapult Venture announced that they have provided funding to Liverpool-based molecular diagnostics company, Biofortuna Limited. The funding will be used to launch the company’s first diagnostic genotyping products and to allow it to continue development of its future product pipeline. The management team is ... http://www.biofortuna.com/index.php/news/biofortuna-limited-secures-1-06m-investment/ Lab901 (Edinburgh, UK) and Biofortuna (Liverpool, UK) today announced that they will collaborate on the launch of an automated PCR based diagnostics system for the rapid detection of certain HLA-related diseases such as Coeliac disease. Lab901 will be optimising its automated ScreenTape® PCR diagnostics platform for use with Biofortuna's range ... http://www.biofortuna.com/index.php/news/biofortuna-and-lab901-to-collaborate-on-rapid-genotyping-projects/ Biofortuna were today approved by Lloyds Register Quality Assurance for the design and manufacture of genotyping and phenotyping in-vitro diagnostic products which enables us to sell CE marked products. The rapid progress in quality management is testament to the dedication and skill of our quality team and our consultant Dave Ashworth ... http://www.biofortuna.com/index.php/news/biofortuna-achieve-iso-90012008-and-iso-134852003/ Over 200 people from the Northwest's biomedical sector gathered last night (Thursday 12th November) at the prestigious annual Northwest Biomedical Awards at Mere Golf and Country Club.  The awards, organised by Bionow, the Northwest Regional Development Agency's (NWDA) biomedical cluster support group, were a resounding success and showcased the very ... http://www.biofortuna.com/index.php/news/biofortuna-awarded-the-biomedical-start-up-company-of-the-year-sponsored-by-baker-tilly/ Biofortuna genotyping products utilise novel platforms from our exciting collaborators. More product information will appear here closer to launch. http://www.biofortuna.com/index.php/products/platforms/ More details will appear here along with our collaborators' information closer to launch. http://www.biofortuna.com/index.php/products/transplant-monitoring/